Engineering the Future of Longevity R&D: The Case for AI-Driven, Integrated Biotechnology Ecosystems
Year: 2025
Type: article
Abstract: The escalating cost, extended timelines, and low success rates in pharmaceutical research demand a rethinking of biotechnology R&D infrastructure to more efficiently discover and deliver novel therapeutics to an increasingly aging population. We introduce the concept of the AI-Integrated Biotechnology Hub, a purpose-built research ecosystem uniting residential, commercial, clinical, and research facilities under a central, AI-driven operating system. The hub functions as a multi-sided platform that unites health data collection, smart living environments, and federated learning to enable secure, privacy-preserving biomedical and longevity research. By integrating real estate, biotechnology facilities, research hospitals, and community services, the model maximizes data utility, accelerates drug discovery, and enhances resident well-being. Transparency, accountability, and ethical stewardship are critical pillars of governance, enacted through dynamic consent, data trusts, and multi-stakeholder oversight. Designed to be scalable across urban and vertical architectures, this paradigm represents a potential approach that may enable more efficient research workflows to improve healthspan, foster innovation, and reshape the economics of global drug development.
Source: Aging and Disease
Authors: Alex Zhavoronkov, Chuen Yan Leung
Institution: Insilico Medicine (United States)
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,000
OpenAlex ID: W4417427348
FWCI:
Cites:
Cited by:
Related to: